Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs STMicroelectronics NV (STM) Price & Performance

Incyte CorporationTrade
STMicroelectronics NVTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs STMicroelectronics NV — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while STMicroelectronics NV trades at $52.06 (market cap $48.14B). The key difference: STMicroelectronics NV is far larger — about 2.1× Incyte Corporation's market cap, and STMicroelectronics NV pays a 0.68% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and STMicroelectronics NV for 64 Days on average.

INCYSTM
Market Cap
$22.85B$48.14B
Volume
1,927,0299,776,015
Sector
HealthTechnology
52-Week High
$129.93$79.91
52-Week Low
$83.80$21.20
Typical Hold Time
33 Days64 Days
Enterprise Value
$18.35B$45.66B
Dividend Yield
—0.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.

Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.

STMicroelectronics NV

STM (STMicroelectronics) is trading at $52.71, down 6.18% over the past 24 hours amid a broader tech selloff. The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment, including a consensus price target of $77.31. Recent financials reveal declining revenue and negative net income margins, though strong cash flow and a solid balance sheet provide stability. Key developments include growing AI data-center revenue projections and new product launches in automotive sensing.

The outlook for STM hinges on execution in AI and automotive segments, with potential upside from analyst targets. Risks include margin pressure from fab transitions and macroeconomic volatility. Investors should weigh strong institutional support against near-term profitability challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INCY
100% Buy0% Sell
Avg holding period · 33 Days
STM
100% Buy0% Sell
Avg holding period · 64 Days

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY →

About STMicroelectronics NV

A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.

Read more on STM →